DocuSign's revenue growth has slowed ... value offering is supported by feature-rich software. Management gave an insight into these developments in the latest earnings, stating that its product ...

In this analysis, we delve into the analyst ratings and average 1-year price targets of Bentley Systems, Docusign and Guidewire Software, three key industry players, offering insights into their ...

Aragon Research Publishes Landmark Report: The Aragon Research Globe™ for Workflow and Content Automation, 2025 ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

DocuSign's IAM is rapidly scaling, now >20% of new direct deals, and is set to drive growth and margin expansion. Check out ...

Investors might also notice recent changes to analyst estimates for DocuSign. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates ...

DocuSign (DOCU) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Analyst Jason Kolbert says, “The mechanistic rationale is supported by both preclinical and translational research, positioning PrimeC as a multimodal therapy in a field still dominated by ...

That’s why the company might have a shot at tackling the industry Goliath, Docusign. Because the startup makes its money from transaction fees for any money movement facilitated by its ...

D. Boral Capital initiated coverage on NeuroSense on Monday with a Buy rating and a price forecast of $14. Analyst Jason Kolbert says, “The mechanistic rationale is supported by both preclinical and ...